Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors [Phase 1]
This Phase 1 trial assesses safety, tolerability, and preliminary efficacy of lomvastomig, a PD-1/TIM-3 bispecific antibody, in adults with …
-
CLINICAL_TRIALS trial_result · 2025-08-19Clinical Trial Update: E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma [Phase 1]
Phase 1 study evaluating E6201 in combination with dabrafenib for central nervous system metastases from BRAF V600-mutated metastatic melano…
-
CLINICAL_TRIALS trial_result · 2025-08-19Clinical Trial Update: Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma [EARLY_Phase 1]
Early-phase trial evaluating a combination of PD-1 blockade, CD137 agonism, and adoptive cell therapy for metastatic melanoma has completed.
-
CLINICAL_TRIALS trial_result · 2025-08-17Clinical Trial Update: Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology [NA]
A completed clinical trial evaluating whether therapeutic patient education can reduce the toxicity associated with immune checkpoint inhibi…
-
CLINICAL_TRIALS trial_result · 2025-08-15Clinical Trial Update: Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies [Phase 1]
Phase 1 dose-escalation and expansion study of intratumoral mRNA-2752 in advanced malignancies has completed, with expansion cohorts in seve…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-08-15Clinical Trial Update: A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
A clinical trial update for SNS-101 (anti-VISTA) as monotherapy and in combination with cemiplimab in adults with advanced solid tumors, cur…
-
CLINICAL_TRIALS trial_result · 2025-08-14Clinical Trial Update: HS-IT101 Injection in the Treatment of Advanced Melanoma [Phase 1]
This clinical trial update reports Phase 1 testing of HS-IT101 injection for advanced melanoma, with enrollment ongoing by invitation.
-
CLINICAL_TRIALS trial_result · 2025-08-14Clinical Trial Update: Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors [Phase 1]
A Phase 1 trial evaluating tovorafenib (DAY101) alone or with pimasertib for melanoma and other solid tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-08-13Clinical Trial Update: Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma [Phase 1]
A Phase 1 safety study evaluating a dendritic cell–based cancer vaccine in melanoma has been completed.
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer [Phase 1]
Phase 1 safety study evaluating enoblituzumab (MGA271) in combination with pembrolizumab or MGA012 in patients with refractory cancers. Resu…
-
CLINICAL_TRIALS trial_result · 2025-08-08Clinical Trial Update: Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2 [NA]
Phase 2 trial investigating an end-of-life conversation game to engage cancer patients in advance care planning; the study is currently acti…
-
CLINICAL_TRIALS trial_result · 2025-08-07Clinical Trial Update: Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC) [Phase 2]
Phase 2 trial evaluating pembrolizumab in combination with bevacizumab for treatment of brain metastases in metastatic melanoma or non-small…
-
CLINICAL_TRIALS trial_result · 2025-08-07Clinical Trial Update: TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma [Phase 1]
Phase 1 trial evaluating TILT-123, an oncolytic adenovirus encoding TNF-α and interleukin-2, used with tumor-infiltrating lymphocyte therapy…
-
CLINICAL_TRIALS trial_result · 2025-08-07Clinical Trial Update: Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 [Phase 1]
Phase 1 trial evaluating the combination of oncolytic adenovirus TILT-123 with Avelumab in solid tumors that progressed after anti-PD-(L)1 t…
-
CLINICAL_TRIALS trial_result · 2025-08-05Clinical Trial Update: Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases [NA]
This update notes a terminated clinical trial at the University of Southern California evaluating precise dynamic contrast-enhanced MRI (DCE…
-
CLINICAL_TRIALS trial_result · 2025-08-01Clinical Trial Update: Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma [Phase 1]
This Phase 1 clinical trial update assesses the safety of combining SBRT with an anti-PD-1 therapy (nivolumab) and an anti-IL-8 agent. The s…
-
CLINICAL_TRIALS trial_result · 2025-07-31Clinical Trial Update: MGC018 With or Without MGA012 in Advanced Solid Tumors [Phase 1, Phase 2]
This clinical trial update reports results from the combination of MGC018 with or without MGA012 (pembrolizumab) in advanced solid tumors. T…
-
CLINICAL_TRIALS trial_result · 2025-07-30Clinical Trial Update: Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma [Phase 1]
Phase 1 trial evaluating Camu-Camu prebiotic with immune checkpoint inhibition in patients with advanced non-small cell lung cancer and mela…
-
CLINICAL_TRIALS trial_result · 2025-07-24Clinical Trial Update: OH2 Injection in Combination With HX008 for Melanoma. [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating OH2 Injection in combination with HX008 for melanoma, and the study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-07-22Clinical Trial Update: Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma [Phase 2]
A Phase 2 clinical trial investigating ways to overcome primary resistance to immunotherapy in metastatic melanoma has been completed.
-
CLINICAL_TRIALS trial_result · 2025-07-22Clinical Trial Update: Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) [Phase 2]
Phase 2 study CA209-260 in advanced melanoma and bladder cancer examined the relationship between tumor mutation burden and predicted neoant…
-
CLINICAL_TRIALS trial_result · 2025-07-18Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) [Phase 1, Phase 2]
The trial completed Phase 1/2 evaluating multiple treatment combinations in melanoma. Results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-07-15Clinical Trial Update: Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma [Phase 2]
A Phase 2 trial evaluating the combination of nivolumab and axitinib in anti-PD-1 refractory advanced melanoma has completed enrollment and …
-
CLINICAL_TRIALS trial_result · 2025-07-14Clinical Trial Update: Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors [Phase 1]
Phase 1 study evaluating the combination of focused ultrasound ablation with PD-1 antibody blockade in advanced solid tumors has been termin…
-
CLINICAL_TRIALS trial_result · 2025-07-11Clinical Trial Update: Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy
This clinical trial update reports results from an observational study of nivolumab as monotherapy or in combination with ipilimumab in part…